Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 2, 2007, Pages 107-111

  Secmeer, Gulten ^a   Devrim, Ilker ^a   Kara, Ates ^a   Ceyhan, Mehmet ^a   Cengiz, Bulent ^a   Kutluk, Tezer ^a   Buyukpamukcu, Munevver ^a   Yetgin, Sevgi ^a   Tuncer, Murat ^a   Uludag, Ali Kerem ^a   Tezer, Hasan ^a   Yildirim, Inci ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

CRP; Neutropenic fever; Pediatric; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CALCITONIN; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; IMMUNOASSAY; INFECTION; MALE; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY;

EID: 33846786790     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180320b5b     Document Type: Article

References (16)

1. Südhoff T, Giagounudis A, Karthaus M, et al. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy. 2000;46:77-85.
2. Fleischhach G, Kambeck I, Cýpýc D, et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. B J Haematol. 2000;111:1093-1102.
3. Persson L, Söderquist B, Engervall P, et al. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol. 2005;74:297-303.
4. Engervall PA, Stiernstedt GT, Gunthier GC, et al. Trimethoprim- sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastin as second empirical therapy in febrile neutropenic patients with hematological disorders. J Chemother. 1992;4:99-106.
5. Arber C, Passweg JR, Fluckiger U, et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis. 2000;32:515-520.
6. Kushner I. The acute phase response: an overview. Methods Enzymol. 1988;163:373-383.
7. Assicot M, Gendrel D, Carsin H, et al. High serumprocalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515-518.
8. Beune G, Bienvenu F, Pondarre C, et al. Serum procalcitonin rise in only slightly in two cases of disseminated aspergillosis. Infection. 1998;26:168-169.
9. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines or the use of antimicrobial agents in neutropenic patients with cancer by Infectious Diseases Society of America. Clin Infect Dis. 2002;34:730-751.
10. Heney D, Lewis IJ, Evans SW, et al. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis. 1992;165:886-890.
11. Katz JA, Mustafa MM, Bash RO, et al. Value of C-reactive protein determination in the initial diagnostic evaluation of febrile, neutropenic child with cancer. Ped Infect Dis J. 1992;11:708-712.
12. Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediat Infect Dis J. 1997;16:735-747.
13. Engel A, Mack E, Kern P, et al. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram negative bacteremia and complicated infection in neutropenic cancer patients. Infection. 1998;26:213-221.
14. Südhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy. 2000;46:77-85.
15. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J. 2000;19:679-688.
16. Sauer M, Tiede K, Fuchs D, et al. C-reactive protein and endotoxin after bone marrow transplantation: identification of children at high risk of morbidity and mortality from sepsis. Bone Marrow Transplant. 2003;31:1137-1142.